Article
CCR5/delta(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. NIAID AIDS Clinical Trials Group Protocol 241 Virology Team.
The Journal of infectious diseases - 1 Jun 1998
D'Aquila R T, Sutton L, Savara A, Hughes M D, Johnson V A
Abstract excerpt
Mechanisms underlying the delay in dominance of syncytium-inducing (SI) phenotype HIV-1 (human immunodeficiency virus type 1) in vivo are unknown. Both random mutational events and selective pressures operative only late in the disease process have been suggested to underlie the shift from CCR5 to alternative coreceptor usage. Among the moderately advanced patients who entered AIDS Clinical Trials Group protocol...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.